PIVAC 2018 was held in Oslo, co-organized by the department of Cell Therpay. The conference permitted to share new advance in the field of vaccination and future prospects for immunotherapy.
Combinatorial CAR design improves target restriction
J Biol Chem, 100116 (in press)
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
Front Immunol, 11, 572172
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther, 29 (3), 1199-1213